Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Product Suite, an integrated solution, which includes proprietary engineered nanoparticles, consumables, automation instrumentation, and data analysis software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company also offers Proteograph ONE, a third-generation assay; Proteograph DIRECT, which provides an automated approach for direct digestion of samples for bottom-up LC-MS proteomic analysis; and Proteograph Analysis Suite, a data analytics software suite designed to support quality control, data management, and interpretation of Proteograph output which is currently offered as a cloud-based solution. It markets and sells its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.…
Seer, Inc. Q3 2026 Earnings Call Summary
Seer (NASDAQ: SEER) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 124 employees.
The shares were at 1.360 USD on 20 November 2026, down 37.0% over 52 weeks. Its 52-week range is 1.330 USD to 2.375 USD: the price is 42.7% below the high and 2.3% above the low.
Its market capitalisation is 75.91M USD.
Seer reports return on equity of -28.4%, an operating margin of -469.9% and revenue down 3.4% year over year.
It holds more cash than debt, a net cash position of 134.15M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock, with an average rating of Strong Buy; their mean price target of 4.000 USD is 194.1% above the current price. The next earnings report is expected on 25 February 2027.